On July 20, 3SBio rose 5.51% in regular trading, trading at HK$16.96/share, with turnover of approximately HK$162 million.

On the news front, the biotechnology sector saw broad-based strength, with Remegen up 8.13%, SKB Bio up 7.63%, Akeso up 6.51%, Innovent Bio up 5.06%, and BeiGene up 4.2%, reflecting significant sector linkage. Additionally, 3SBio had previously plunged 9.83% on July 17 after Orient Securities disclosed a disposal of 6.131 million shares at approximately HK$17.87 per share, totaling around HK$110 million. Orient Securities' post-disposal holding fell to approximately 177 million shares, representing a 6.97% stake. The sharp prior decline created short-term oversold rebound demand, which combined with the sector-wide rally to drive today's recovery.

3SBio is a biopharmaceutical company primarily engaged in the development, manufacturing, and commercialization of biologics including Tebiao, Yibiao, and Yisaipu, alongside its CDMO business.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)